The latest news from academia, regulators
research labs and other things of interest
Posted: November 11, 2008
The xCELLigence System Allows Real-Time Monitoring of Cell Adhesion and Spreading
(Nanowerk News) The xCELLigence System from Roche Applied Science enables researchers to monitor and quantitatively assess cell attachment and spreading in real-time. The technique is non-invasive and does neither require lab- and cost-intensive cell labeling nor cell lysis or fixation. With this quick and economical method, the user can monitor the effect of matrix proteins on biological events in one single experiment.
ECM proteins such as fibronectin interact with specific cell surface receptors, the integrins. Integrins not only mediate cellular adhesion but upon interaction with ECM proteins also initiate an intracellular signaling cascade that directs various cellular processes. Cellular adhesion on different biological surfaces is a dynamic, integrated process that requires the participation of cell surface receptors, structural and signaling proteins, and the cytoskeleton.
In an experiment to test the xCELLigence System, E-Plates were coated with fibronectin or a control peptide. NIH3T3 cells were applied to the coated wells and the extend of cell adhesion and spreading, measured as changes in impedance and recorded in arbitrary Cell Index (CI) units, was monitored over time. The CI increased dramatically when cells were applied to fibronectin-coated wells, but increased only slowly when applied to wells treated with the control peptide. In addition, impedance measurements showed that the extent of cell adhesion on the fibronectin-coated cell sensor array was dependent on fibronectin concentration (as confirmed by manual cell counts). The data support the notion that with this technology, cell attachment and spreading can be quantitatively assessed in real-time under label-free conditions.
To test whether perturbation of integrin receptor function can be assessed using the impedance-based technology, fibroblasts were incubated in the presence of an integrin inhibitor peptide, and then plated on fibronectin-coated E-Plates. Using the xCELLigence System, it was confirmed that the inhibitor blocked NIH3T3 cell adhesion and spreading in a concentration-dependent manner while a control peptide had no effect.
The effect of actin-disrupting agents on cell adhesion and spreading was also monitored using the xCELLigence System. Fibroblasts were incubated in the presence of an actin polymerization inhibitor, and then plated on fibronectin-coated E-Plates. The presence of actin polymerization inhibitor in fact inhibited cell attachment and spreading in a concentration-dependent manner.
The group of signaling proteins that participate in integrin-mediated cell attachment and spreading include the Src family of non-receptor tyrosine kinases. It was shown in a research study that interference with Src expression or Src activity, either via siRNA interference or small molecule inhibitors such as PP2, resulted in the disruption of adhesion and spreading of human cancer cells as monitored with the xCELLigence System.
The xCELLigence System, originally invented by ACEA Biosciences, San Diego, USA is based on an impedance-based assay system. It uses special microplates (E-Plates) integrated with electronic cell sensors arrays in conjunction with a real-time cell electronic sensing system.
For more information on the technology, please visit www.xcelligence.roche.com.
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totalled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 80,000 people. Additional information is available on the Internet at www.roche.com.